Search / Trial NCT06616636

A Phase Ib Study of Rezatapopt in Combination with Azacitidine or Azacitidine and Venetoclax in Patients with TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)

Launched by M.D. ANDERSON CANCER CENTER · Sep 25, 2024

Apply for Trial

Trial Information

Current as of October 08, 2024

Not yet recruiting

Keywords

Description

Primary Objective: To assess the safety and tolerability of rezatapopt in combination with AZA +/- VEN in patients with TP53Y220C -mutant myeloid malignancies (AML, MDS) Secondary Objectives: 1. To determine the clinical efficacy of rezatapopt in combination with AZA +/- VEN in R/R and newly diagnosed patients with TP53Y220C -mutant myeloid malignancies 2. To assess event free survival (EFS) and overall survival (OS) in patients receiving rezatapopt in combination with AZA +/- VEN 3. To assess duration of response in patients receiving rezatapopt in combination with AZA +/- VEN 4. Charac...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Patient is ≥ 18 years of age at the time of signing the informed consent form (ICF).
  • 2. Patient is willing and able to adhere to the study visit schedule and other protocol requirements.
  • 3. Patient has relapsed or primary refractory AML or MDS (cohort 1)
  • 4. Patient has newly diagnosed AML or MDS (cohort 2) who is considered not eligible for intensive chemotherapy which must be defined as: Age 75 years or older, or Age 18 to 74 years with at least one of the following comorbidities:
  • i. Severe cardiac disorder (eg, congestive heart failure requiring treatment, ejection fraction
  • * 50%, or chronic stable angina). ii. Severe pulmonary disorder (eg, DLCO ≤65% or forced expiratory volume in 1 second \[FEV1\]
  • * 65%). iii) Creatinine clearance ≥30 mL/min to \<45 mL/min. iii. Moderate hepatic impairment with total bilirubin \>1.5 to ≤3.0 × upper limit of normal (ULN) iv. ECOG performance status of \>2
  • 5. Any other comorbidity that per the investigator renders a patient inappropriate for intensive chemotherapy.
  • 6. Patients with MDS must be classified as MDS-IB1 or IB2 as per WHO 2022 criteria32
  • 7. TP53Y220C mutation confirmed by CLIA-approved local testing with a variant allele frequency \>2%.
  • 8. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of ≤2
  • 9. Patient has adequate organ function defined as:
  • 1. Serum aspartate aminotransferase/serum glutamic oxaloacetic transaminase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) ≤ 3 x ULN, unless considered due to leukemic organ involvement.
  • 2. Serum total bilirubin ≤ 1.5 x ULN. Higher levels are acceptable if these can be attributed to ineffective erythropoiesis, leukemia organ involvement or Gilbert\'s syndrome.
  • 3. Serum creatinine \< 2 x ULN or creatinine clearance \> 40 mL/min based on validated glomerular filtration rate (GFR) estimation (Cockcroft-Gault, CKD-epi, or MDRD equations).
  • 10. Females of childbearing potential may participate provided they have a negative serum or urine pregnancy test at screening and a negative serum OR urine pregnancy test within 72 hours of starting on treatment. They also must agree to either abstain from sexual intercourse or use two forms of a highly effective method of contraception while on study and up to 3 months after the last dose of the study drug.
  • 11. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) 14 days prior to study entry and for the duration of study participation. This includes all female patients between the onset of menses and 55 years unless the patient presents with an applicable exclusionary factor which may be one of the following:
  • Postmenopausal (no menses in greater than or equal to 12 consecutive months). History of hysterectomy or bilateral salpingo-oophorectomy. Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy).
  • History of bilateral tubal ligation or another surgical sterilization procedure.
  • • Approved methods of birth control are as follows: Hormonal contraception (i.e. birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject/Partner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
  • Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 3 months after completion of investigational agent administration.
  • 12. Ability to understand and the willingness to sign a written informed consent document.
  • Exclusion Criteria:
  • 1. Patient has received prior chemotherapy, targeted therapy, immunotherapy, or treatment with an investigational anticancer agent within 14 days or 5 half-lives (if half-life is known), whichever is shorter, before receiving their first dose of study drug.
  • 2. Patient has received radiotherapy within 14 days.
  • 3. Patients with acute promyelocytic leukemia
  • 4. Subject has immediate life-threatening, severe complications of leukemia such as uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated intravascular coagulation.
  • 5. Patients with active, uncontrolled leukemia involvement of the CNS
  • 6. Subject has known active viral infection with human immunodeficiency virus (HIV), or active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)
  • 7. Subject is known to have dysphagia, short-gut syndrome, gastroparesis, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally.
  • 8. Subject has active uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment).
  • 9. Patient has any unresolved toxicities from prior anti-cancer therapy greater than Grade 1 at the time of starting study treatment with the exception of alopecia and Grade 2 prior chemotherapy induced neuropathy.
  • 10. Patient has had major surgery within 2 weeks prior to the planned start of study treatment.
  • 11. Female subject who is pregnant or lactating.
  • 12. History of allergic reactions attributed to compounds of similar chemical or biologic composition to azacitidine, venetoclax, rezetapopt or other agents used in study.

About M.D. Anderson Cancer Center

The University of Texas MD Anderson Cancer Center is a leading institution dedicated to cancer care, research, education, and prevention. As one of the world’s most respected cancer centers, MD Anderson focuses on innovative treatment approaches and groundbreaking clinical trials aimed at improving patient outcomes. With a multidisciplinary team of experts and state-of-the-art facilities, the center is committed to advancing cancer research and providing comprehensive, personalized care to patients. MD Anderson's clinical trials play a pivotal role in translating scientific discoveries into effective therapies, positioning the center at the forefront of cancer treatment and research.

Locations

Houston, Texas, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0